ClinicalTrials.gg
RecruitingNCT07081568Updated Oct 7, 2025

Research on Binaural Synchronous Vagus Nerve Regulation of Sensorimotor Disorders After Cerebral Infarction

An interventional study of transcutaneous auriculai vagus nerve stimulation in Cerebral Infarction, sponsored by Nanchang University Affiliated Rehabilitation Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-10-07.

Sponsored by Nanchang University Affiliated Rehabilitation Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 58 studies in Cerebral Infarction with a site in China — 16 open to participants now, 18 under way, 3 of them phase 3. Cerebral Infarction · China.

Planned enrollment
30th of 37
40 · median 210
Started
2025
with 3 others
No phase
13 of 58
4 open now
Primary completion
2027-06
later than 11 of 17 live
Registered
51st of 58
by date

Among the 58 studies in Cerebral Infarction with a site in China, this one is the 30th largest by planned enrollment of the 37 interventional ones that give a count, is one of 4 that started in 2025, is one of 13 with no phase, reaches primary completion later than 11 of the 17 other live ones, and was the 51st registered.

Cerebral Infarction

219 studies on the registry are indexed under Cerebral Infarction; 46 are open to participants now.

Browse Cerebral Infarction studies →

Open to participants now

16 of the 58 studies in Cerebral Infarction with a site in China are open now. Recruiting first, the newest first:

10 more — sign in →

All 16 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 27 Cerebral Infarction studies recruiting now, 19 (70%) set no upper age limit and none (0%) stop at 75 or younger; 2 take children under 18; 2 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 58 studies in Cerebral Infarction with a site in China, or all of them as a file.
02

Study summary

The aim of this study is to determine the efficacy and safety of binaural synchronous vagus nerve regulation in the treatment of patients with sensory and motor dysfunction after cerebral infarction through a randomized controlled clinical study, and to provide high-quality evidence support for binaural synchronous vagus nerve regulation in the treatment of cerebral infarction.

Read the detailed description

The research subjects were first-onset cerebral infarction and were recruited at the Affiliated Rehabilitation Hospital of Nanchang University (the Fourth Affiliated Hospital). Based on the estimated sample size, a total of 40 patients were included in this study. The randomization grouping protocol divided 40 patients into the experimental group and the control group in a 1:1 ratio. Experimental group: Received synchronous vagus nerve regulation in both ears. Control group: Received false stimulation. The randomization procedure was carried out by independent statisticians who were not involved in the implementation and statistics of the study. The trial secretary placed the generated random numbers and groups respectively into opaque envelopes. After the patients were confirmed to be included in the group, the project leader opened the envelopes numbered in sequence to complete the grouping. This study was A double-blind design, using a unified binaural vagus nerve electrical stimulation device (JY-VNS-200, Jiangxi Jingyi Medical Technology Company Limited.). To achieve researcher blindness, the device was preset in A/B mode, with one mode being true stimulation and the other mode being false stimulation. After the experiment, unblinding was performed by personnel who were not involved in the study. During the experiment, the patients did not know whether they were receiving actual treatment or a placebo. The patients were blind. Meanwhile, the evaluators and statistical analysts were unaware of the grouping of the patients.

03

Conditions studied

  • Cerebral Infarction

Keywords

  • Ischemic Stroke
  • Transcutaneous Auriculai Vagus Nerve Stimulation
  • Rehabilitation for Cerebral Infarction
  • Neuromodulation
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with first-episode ischemic stroke within 7 to 14 days of onset;
  • Be over 18 years old;
  • The skin at the irritated area remains intact;
  • The form has been signed.

Exclusion criteria

Exclusion Criteria:

  • Severe cognitive dysfunction (≥19);
  • Peripheral limb movement limiting factors (fractures);
  • History of major neurological and mental disorders in the past;
  • Uncontrollable limb and facial muscle twitching, and spontaneous profuse sweating;
  • Intracranial shunt pumps, metal implants
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
40 participants (estimated)

Study arms

  • No intervention
    Sham Stimulation Group

    Sham Stimulation Group received sham stimulation using device B, which had identical appearance, interface parameters, and physical sensation but no therapeutic effect. Stimulation parameters were set as follows: sinusoidal waveform; pulse width of 200μs; frequency of 20Hz; current adjusted to 0mA by the investigator; single session duration of 30 minutes. After each session, the device was disinfected with 75% alcohol. Treatment was administered once daily, 5 days per week, for a total duration of 4 weeks.

  • Experimental
    transcutaneous auriculai vagus nerve stimulation

    The patient was positioned in a supine position. Two stimulating electrodes were placed on the bilateral concha cymba and concha cavum. Stimulation parameters were set as follows: sinusoidal waveform; pulse width of 200μs; frequency of 20Hz; initial intensity of 2mA. Each treatment session lasted 30 minutes. Treatment was administered once daily, 5 days per week, for a total duration of 4 weeks. After each treatment session, the device was disinfected with 75% alcohol.

    Device: transcutaneous auriculai vagus nerve stimulation

Interventions

  • Devicetranscutaneous auriculai vagus nerve stimulation

    During bi-ear synchronous vagus nerve stimulation, the patient was positioned in a supine position. Two stimulating electrodes were placed bilaterally in the concha cymba and concha cavum of the ears. The patient received treatment for 30 minutes per session, once daily, 5 days per week, for a total of 4 weeks. Following each treatment session, the device was disinfected with 75% alcohol.

06

What researchers measure

Primary outcomes

  1. Motor function score

    Motor function was evaluated using the Fugl-Meyer Assessment of Motor Recovery after Stroke (FMA) .The assessment was performed three times. The minimum score for the Fugl-Meyer Assessment (FMA) is 0, and the maximum score is 226.A higher score on the FMA indicates better motor recovery/function and a lower level of motor impairment.

    Time frame: Before the start of treatment, the last week before the end of treatment, and the third month after the onset of the disease

  2. Overall functional score

    Assess three times using the National Institutes of Health Stroke Scale. The maximum score on the scale is 42, and the minimum score is 0.Higher scores denote more severe stroke symptoms.

    Time frame: Before the start of treatment, the last week before the end of treatment, and the third month after the onset of the disease

  3. Transcranial Magnetic Stimulation combined with Electroencephalography(TMS-EEG)

    Amplitude and latency of key TMS-evoked potential (TEP) components ( N100, P180, N200) recorded from specific scalp electrodes (Fz, Cz, Pz) following single-pulse TMS over the dorsolateral prefrontal cortex (DLPFC).

    Time frame: Before the start of treatment, the last week before the end of treatment, and the third month after the onset of the disease

  4. Sensory function score

    Using the Eastern Michigan Neuropathy Symptom Score Assessment sensory scale for assessment, the lowest possible score is 0 and the highest is 100. A higher score indicates that the patient's neurological symptoms are more severe and that the degree of nerve damage is more apparent.

    Time frame: Before the start of treatment, the last week before the end of treatment, and the third month after the onset of the disease

Secondary outcomes

  1. Cognitive function score

    Using the Mini-Mental State Examination scale for assessment, the minimum score is 0 and the maximum score is 30. The higher the score, the better the cognitive function of the examinee, indicating a normal cognitive state.

    Time frame: Before the start of treatment

07

Study locations

1 of 1 sites recruiting
  • The Fourth Affiliated Rehabilitation Hospital of Nanchang University
    Nanchang, Jiangxi 330009, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Jun 2027, 24 months after the start.

Of 27 interventional studies with no phase under Cerebral Infarction, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 49. This study's planned 24 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 19, 2025
First posted
Jul 23, 2025
StartActual
Jun 25, 2025
Primary completionEst.
Jun 30, 2027
CompletionEst.
Dec 31, 2027
Last update
Oct 7, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 7, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07081568
Lead sponsor
Nanchang University Affiliated Rehabilitation Hospital
Responsible party
Wentao Zeng (Doctor of Medicine, Nanchang University Affiliated Rehabilitation Hospital) — Principal investigator
First posted
Jul 23, 2025
Start date
Jun 25, 2025
Primary completion
Jun 30, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Oct 7, 2025

Study contacts

Han Jinjing Attending Physician
Contact
515476321@qq.com
13672202061

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion